Cell Source (Cell Source) Momentum Rank : 0 (As of May. 26, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Cell Source Momentum Rank?

Cell Source has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Cell Source Momentum Rank Related Terms

Thank you for viewing the detailed overview of Cell Source's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell Source (Cell Source) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

57 West 57th Street, Suite 400, New York, NY, USA, 10019

Website

https://www.cell-source.com

Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.

Executives

George Verstraete	director	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave	director, 10 percent owner	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner	10 percent owner
Yoram Drucker	director	31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown	director	100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat	director, officer: CEO and CFO	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty	director	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman	director, 10 percent owner	C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines

From GuruFocus

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source's Scientific Advisory Board

By PRNewswire PRNewswire • 02-25-2021